MacroGenics is a US-based biopharmaceutical company that develops and sells antibody-based cancer treatments, primarily focusing on immuno-oncology product candidates. The company's flagship product is MARGENZA, which is approved for the treatment of metastatic HER2-positive breast cancer. MacroGenics also has a range of investigational products in the pipeline targeting various cancer types, autoimmune diseases, and infectious diseases, and has several partnerships with other pharmaceutical companies.